5F-MDMB-PICA (5F-MDMB-2201): Complete Fatal Toxicology, Dependence & Safety Monograph

5F-MDMB-PICA (5F-MDMB-2201): Complete Fatal Toxicology, Dependence & Safety Monograph

Emergency synthetic-cannabinoid warning: Seizure, profound unresponsiveness, abnormal breathing, collapse, severe agitation/psychosis, repeated vomiting with reduced consciousness, chest pain, or dangerous heart-rate/blood-pressure changes after an unknown "Spice"/vape/herbal product requires urgent medical care.

Quick answer

5F-MDMB-PICA, also called 5F-MDMB-2201, is a potent synthetic cannabinoid receptor agonist with documented human intoxications, impaired-driving/criminal cases, child poisoning and fatalities.

It is chemically distinct from 5F-MDMB-PINACA, also called 5F-ADB.

That one-letter scaffold difference—PICA vs PINACA—matters.

5F-MDMB-PICA has an indole core.

5F-MDMB-PINACA/5F-ADB has an indazole core.

They are different controlled substances with different analytical standards and metabolism.

Identity

History and emergence

5F-MDMB-PICA appeared in European "legal high"/Spice markets around 2016.

Early analytical papers identified it in:

• brown powder;
• herbal incense;
• human urine.

Its emergence followed a familiar SCRA pattern: when older cannabinoids were controlled, closely related high-efficacy analogues entered the market.

By 2020, enough human casework had accumulated for a 12-case dedicated series.

5F-MDMB-PICA vs 5F-MDMB-PINACA / 5F-ADB

These names are easy to confuse.

5F-MDMB-PICA

• indole core;
• also called 5F-MDMB-2201.

5F-MDMB-PINACA

• indazole core;
• widely called 5F-ADB.

They share some functional features as potent synthetic cannabinoid agonists, but their:

• exact receptor potency;
• metabolism;
• forensic standards;
• legal identity

are not interchangeable.

A high-quality toxicology page should never collapse them into one molecule.

Pharmacology

A 2020 pharmacology/metabolism study directly evaluated 5F-MDMB-PICA activity at cannabinoid receptors.

It showed potent and efficacious CB1 receptor agonism.

Synthetic cannabinoids like 5F-MDMB-PICA can behave differently from THC because many are highly efficacious receptor agonists rather than lower-efficacy partial agonists.

This helps explain why SCRA intoxication can involve severe neurologic and cardiovascular effects not typical of ordinary cannabis intoxication.

Why receptor potency cannot become a dose chart

CB1 potency varies by:

• assay;
• signaling endpoint;
• reference agonist;
• stereochemistry;
• receptor expression.

A nanomolar EC50 does not tell a person what amount of an herbal mixture or powder is safe.

SCRA products also have notorious hot-spot/homogeneity problems.

12-case human/forensic series

A 2020 Forensic Science International paper described 12 cases with proven 5F-MDMB-PICA exposure.

They included:

• three fatalities;
• four DUID cases;
• five other criminal cases.

Measured blood/serum concentrations ranged from:

• 0.1 to 16 ng/mL.

Nine of 12 cases also contained other psychoactive substances.

Common co-exposures included:

• alcohol;
• cannabis;
• other synthetic cannabinoids.

In five cases, 4F-MDMB-BINACA was also detected.

What the concentration range tells us

The 0.1–16 ng/mL range establishes that clinically/forensically relevant exposure occurs at very low concentrations.

It does not establish:

• a safe concentration;
• an impairment cutoff;
• a fatal threshold.

Polysubstance use and individual variation make simple concentration categories unreliable.

Fatality evidence

Three fatalities in the 12-case series

The 2020 series directly includes postmortem cases.

Because co-consumption was common, each death needs individual causal interpretation.

Fatal 5F-MDMB-PICA + 4F-MDMB-BINACA intoxication

A 33-year-old man lost consciousness after smoking an unknown substance and died.

At the scene, a pipe and material containing both synthetic cannabinoids were found.

5F-MDMB-PICA concentrations were:

• blood: 0.9 ng/mL;
• urine: 0.1 ng/mL;
• cerebrospinal fluid: 3.2 ng/mL.

4F-MDMB-BINACA was found in cerebrospinal fluid.

This is a confirmed fatal mixed-SCRA exposure, not a 0.9-ng/mL lethal threshold.

Child intoxication

A published case documented intoxication in a 1.5-year-old boy.

5F-MDMB-PICA was initially measured in serum at 298 ng/mL.

The same stored serum was reanalyzed one year later and contained only 17.6 ng/mL.

Eight metabolites were identified in urine.

Why this case matters

It provides two unusually important lessons:

1. children can experience genuine severe exposure to modern SCRAs;
2. parent-drug concentration can change dramatically during storage.

A delayed low concentration may underestimate earlier exposure.

Acute toxicity

Potential severe SCRA effects include:

• agitation;
• panic;
• paranoia/psychosis;
• profound sedation;
• confusion;
• seizures;
• loss of consciousness;
• vomiting;
• tachycardia or bradycardia;
• hypertension or hypotension;
• chest pain;
• dysrhythmia;
• temperature dysregulation;
• rhabdomyolysis;
• kidney injury;
• death.

No single toxidrome appears in every patient.

Seizures and neurologic toxicity

Seizures are a recurring severe effect across potent SCRAs.

Possible downstream complications include:

• aspiration;
• hypoxia;
• muscle injury;
• metabolic acidosis;
• trauma.

A seizure after an unknown synthetic cannabinoid product is an emergency.

Cardiovascular toxicity

SCRAs can cause:

• tachycardia;
• bradycardia;
• hypertension;
• hypotension;
• chest pain;
• arrhythmia.

The unpredictability reflects both receptor pharmacology and variable product composition.

Psychiatric effects

Possible acute effects include:

• severe anxiety;
• paranoia;
• hallucinations;
• agitation;
• psychosis;
• delirium-like confusion.

People with underlying psychotic/bipolar vulnerability may be at particular risk, although 5F-MDMB-PICA-specific incidence is not quantified.

Interactions

No controlled 5F-MDMB-PICA interaction trials define safe combinations.

Important concerns include:

• alcohol/benzodiazepines → deeper impairment and reduced consciousness;
• opioids → respiratory depression from the opioid component;
• stimulants → greater cardiovascular/behavioral stress;
• other SCRAs → unpredictable cannabinoid agonist load.

Polysubstance exposure was common in the published case series.

Metabolism

5F-MDMB-PICA is rapidly and extensively metabolized.

Human hepatocyte work and authentic case specimens identify transformations including:

• ester hydrolysis;
• oxidative defluorination;
• hydroxylation;
• further oxidation;
• glucuronidation.

Because parent drug can disappear quickly, metabolite selection is crucial.

Human urine, serum and hair metabolomics

A 2021 study compared human:

• urine;
• serum;
• pubic hair.

Researchers identified:

• 47 intact metabolites in urine;
• 15 metabolites in serum;
• parent drug but no metabolites in pubic hair.

Urine was considered the preferred matrix for documenting exposure.

An ester-hydrolysis + glucuronide product was highlighted as an important biomarker.

Why metabolites matter

Parent 5F-MDMB-PICA may be:

• present at low concentration;
• rapidly metabolized;
• unstable during storage.

A well-designed toxicology panel therefore includes both parent and high-value metabolites.

Specimen instability

The child case demonstrates dramatic serum instability over one year.

This means interpretation depends on:

• storage temperature;
• storage duration;
• matrix;
• number of freeze-thaw cycles;
• assay timing.

A low later concentration is not proof that the original exposure was low.

Pharmacokinetics

Controlled human PK remains poorly characterized.

No prospective human study establishes a universal:

• bioavailability;
• time to peak;
• half-life;
• clearance;
• concentration-effect relationship.

Rapid metabolism seen analytically is not equivalent to a safe duration estimate.

Drug testing

Routine cannabis immunoassays

Standard THC metabolite screens do not reliably detect 5F-MDMB-PICA.

A negative cannabis test does not rule out synthetic cannabinoid exposure.

Definitive testing

Methods include:

• LC-MS/MS;
• LC-QTOF/HRMS;
• GC-MS/MS;
• parent + metabolite panels.

A 2024 GC-MS/MS method achieved sub-ng/mL detection in authentic human blood.

Product identity and hot spots

Synthetic cannabinoids may be distributed in:

• herbal mixtures;
• powders;
• vape products;
• paper;
• other carriers.

A sprayed product can be unevenly distributed.

Two pieces from the same packet may not contain the same amount.

That makes package-level concentration claims unreliable without representative chemical analysis.

Tolerance

Human SCRA research indicates tolerance can develop rapidly in frequent users and may develop faster than with high-potency cannabis.

No 5F-MDMB-PICA-specific prospective tolerance study exists.

Tolerance to subjective effects does not mean protection from:

• seizures;
• psychosis;
• cardiovascular collapse;
• product hot spots.

Physical dependence

Frequent synthetic cannabinoid use can produce physical dependence.

5F-MDMB-PICA-specific incidence is unknown.

Dependence should be distinguished from synthetic cannabinoid use disorder, which involves broader behavioral features such as:

• craving;
• inability to cut down;
• compulsive use;
• continued use despite harm.

Withdrawal

A human survey of SCRA users who had attempted to stop found a mean of multiple withdrawal symptoms.

Common symptoms included:

• sleep problems;
• irritability;
• low mood.

Clinical literature also reports severe SCRA withdrawal with:

• anxiety;
• tachycardia;
• agitation;
• vomiting;
• psychosis;
• seizures in some reports.

Evidence boundary

There is no validated 5F-MDMB-PICA-specific:

• onset;
• peak;
• duration;
• seizure incidence;
• taper protocol.

Do not convert mixed-SCRA withdrawal literature into a molecule-specific clock.

Treatment and support

There is no medication approved specifically for 5F-MDMB-PICA dependence or withdrawal.

Clinical management depends on the actual symptoms and severity.

Urgent care is appropriate for:

• seizure;
• delirium;
• severe psychosis/agitation;
• chest pain;
• persistent vomiting/dehydration;
• major autonomic instability;
• inability to stay safe.

Ongoing problematic use can be addressed through addiction and mental-health care.

Forensic interpretation

Detection does not automatically prove sole causation

The 12-case series often involved other drugs.

Concentration is not dose

Blood concentration depends on:

• timing;
• product heterogeneity;
• metabolism;
• tolerance;
• storage;
• postmortem processes.

Metabolite analysis can be more informative than parent alone

Rapid metabolism and instability make parent-only testing vulnerable to false negatives or underestimation.

Special populations

Controlled safety data are inadequate for:

• pregnancy/breastfeeding;
• children;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• severe psychiatric illness;
• liver/kidney disease.

The published child intoxication demonstrates that pediatric exposure is not theoretical.

Legal status

United States

DEA permanently placed 5F-MDMB-PICA in Schedule I effective April 7, 2022.

It had previously been temporarily controlled.

International

UNODC lists 5F-MDMB-PICA in Schedule II of the 1971 Convention on Psychotropic Substances, scheduled in 2020.

Myths and misconceptions

"5F-MDMB-PICA is the same thing as 5F-ADB."
False. 5F-ADB is 5F-MDMB-PINACA, a different indazole compound.

"A negative THC screen rules out synthetic cannabinoids."
False.

"The 0.1–16 ng/mL case-series range defines safe and fatal levels."
False. Fatal and nonfatal contexts overlap and many cases were polysubstance.

"If the parent drug is gone, there was no exposure."
False. Rapid metabolism and specimen instability make metabolites crucial.

"Synthetic cannabinoid withdrawal is just mild cannabis withdrawal."
Not necessarily. SCRA withdrawal can be substantially more severe.

Evidence ledger

Related evidence

• 5F-ADB / 5F-MDMB-PINACA
• MDMB-4en-PINACA
• ADB-BUTINACA
• Synthetic cannabinoids / Spice
• Research chemicals & NPS evidence map
• Substance Use, Dependence & Harm Reduction hub

Bottom line

5F-MDMB-PICA is not an interchangeable "Spice" ingredient.

It is a specific, potent cannabinoid agonist with documented human fatalities, child intoxication, extensive human metabolite data, low-ng/mL forensic concentrations, major specimen-instability problems, and real dependence/withdrawal concerns.

The most useful safety message is not a potency multiplier.

It is:

identify the exact SCRA, test metabolites as well as parent drug, interpret concentrations cautiously, and treat severe neurologic or cardiovascular symptoms as medical emergencies.